v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating activities:      
Consolidated net income $ 607.3 $ 551.7 $ 700.2
Adjustments to reconcile consolidated net income to net cash provided by operating activities:      
Depreciation and amortization 680.6 619.8 568.6
Stock-based compensation expense 81.6 71.8 62.6
Deferred income taxes (66.9) (70.2) 88.1
Gain on fair market value adjustment and gain on sale of equity investments 0.0 (13.8) (36.8)
Changes in assets and liabilities, excluding effects of acquisitions:      
Accounts receivable, net (66.3) (23.3) (138.6)
Other assets, current and long-term (29.5) (13.0) (22.4)
Current and long-term liabilities, excluding debt 117.7 (6.2) (464.6)
Cash provided by operating activities 1,324.5 1,116.8 757.1
Investing activities:      
Capital expenditures (511.5) (601.3) (624.5)
Acquisitions, net of cash acquired 0.0 (283.8) (433.8)
Cash received from divestitures 0.0 6.9 98.8
Cash used in investing activities (511.5) (878.2) (959.5)
Financing activities:      
Net short-term borrowings (payments) 91.2 (371.2) 242.2
Payments on long-term debt (1,445.6) (579.3) (500.0)
Proceeds from issuance of long-term debt 649.8 872.9 749.3
Dividends paid to Equifax shareholders (193.2) (191.8) (191.1)
Distributions paid to noncontrolling interests (4.6) (45.6) (3.1)
Proceeds from exercise of stock options and employee stock purchase plan 78.2 32.3 16.9
Payment of taxes related to settlement of equity awards (16.8) (17.3) (33.9)
Purchase of redeemable noncontrolling interests 0.0 0.0 (0.4)
Debt issuance costs (5.4) (6.2) (6.2)
Cash (used in) provided by financing activities (846.4) (306.2) 273.7
Effect of foreign currency exchange rates on cash and cash equivalents (13.5) (0.8) (10.8)
(Decrease) increase in cash and cash equivalents (46.9) (68.4) 60.5
Cash and cash equivalents, beginning of period 216.8 285.2 224.7
Cash and cash equivalents, end of period $ 169.9 $ 216.8 $ 285.2

Source